You haven't answered this ever. All you say is that imperfect adherence is common in RCTs, which is not an answer. This isn't an RCT, and it's not about adherence
-
This Tweet is unavailable.
-
-
This Tweet is unavailable.
-
Replying to @c19analysis
You didn't answer this, you just gave a non-response. Presumably you have no idea how many people in any country actually received HCQ, which as I said completely undermines the analysis
1 reply 0 retweets 0 likes -
This Tweet is unavailable.
-
Replying to @c19analysis
I feel like I'm in a Monty Python skit. I've answered them, and you still haven't even come close to addressing mine!
1 reply 0 retweets 1 like -
This Tweet is unavailable.
-
Replying to @c19analysis
Answered: - no study is missing, just misclassified - early treatment unlikely to have benefit based on robust evidence - cbf re-reading your references to find the study you mean - any treatment 'may' be effective, this one appears unlikely to be
2 replies 0 retweets 1 like -
Replying to @GidMK @c19analysis
Now, what proportion of your intervention group actually received HCQ? Simple question!
1 reply 0 retweets 1 like -
This Tweet is unavailable.
Other trials having problems is immaterial. Could Algeria have a smaller % of people treated with HCQ than France? Or India than Canada? Not based on news - actual numbers
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.